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Abstract
Introduction: Disease severity in collagen-induced arthritis (CIA) is commonly assessed by clinical scoring of paw
swelling and histological examination of joints. Although this is an accurate approach, it is also labour-intensive
and the application of less invasive and less time-consuming methods is of great interest. However, it is still
unclear which of these methods represents the most discriminating measure of disease activity.
Methods: We undertook a comparative analysis in which different measurements of inflammation and tissue
damage in CIA were studied on an individual mouse level. We compared the current gold standard methods -
clinical scoring and histological examination - with alternative methods based on scoring of X-ray or micro-
computed tomography (CT) images and investigated the significance of systemically expressed proteins, involved
in CIA pathogenesis, that have potential as biomarkers.
Results: Linear regression analysis revealed a marked association of serum matrix metalloproteinase (MMP)-3 levels
with all features of CIA including inflammation, cartilage destruction and bone erosions. This association was
improved by combined detection of MMP-3 and anti-collagen IgG2a antibody concentrations. In addition,
combined analysis of both X-ray and micro-CT images was found to be predictive for cartilage and bone damage.
Most remarkably, validation analysis using an independent data set proved that variations in disease severity,
induced by different therapies, could be accurately represented by predicted values based on the proposed
parameters.
Conclusions: Our analyses revealed that clinical scoring, combined with serum MMP-3, anti-collagen IgG2a
measurement and scoring of X-ray and micro-CT images, yields a comprehensive insight into the different aspects
of disease activity in CIA.
Introduction
The systemic autoimmune disease rheumatoid arthritis
(RA) is characterized by synovial inflammation followed
by progressive destruction of articular cartilage and sub-
chondral bone. Mouse models are often used to gain
further insight into the pathological mechanisms of joint
inflammation as well as for preclinical evaluation of
therapeutic agents. In this context, collagen induced
arthritis (CIA) is the most widely studied animal model
for RA as it models the similarities in pathology and
immunological processes involved in the disease [1].
Currently, clinical scoring of inflamed paws over time
is the standard method used for quantification of disease
severity. This is followed by histological examination of
joints to assess inflammation, and cartilage and bone
loss. More recently, alternative and less time-consuming
techniques such as scoring of X-ray and micro-com-
puted tomography (micro-CT) images have been
employed. The Larsen score is well established for the
scoring of X-ray pictures and accounts for abnormalities
of the joint space and bone erosions [2,3]. Alternatively,
when performing micro-CT analysis, the number of
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objects per micro-CT slice parameter can be used as an
indicator of bone porosity [4].
Moreover, the application of biomarkers that are
measurable in serum, urine or tissue has become a
topic of increasing interest. Pro-inflammatory cyto-
kines like tumour necrosis factor-a (TNF-a) are
detected in arthritic mice and cartilage degradation
products such as cartilage oligomeric matrix protein
(COMP) and C-telopeptide fragments of type II col-
lagen (CTXII) have been described as potential bio-
markers for cartilage destruction in CIA [5-7].
Furthermore, the production of autoantibodies to type
II collagen (CII) is a typical feature of CIA [8]. Despite
the fact that these methods are regularly used, it
remains unclear which read-out parameters are most
useful when assessing CIA.
We therefore established an analysis platform in which
the degree of inflammation and tissue damage in CIA
was assessed at the level of individual mice. This plat-
form incorporated different scoring methods including
histological examination and techniques based on scor-
ing of X-ray or micro-CT images. Furthermore, systemi-
cally expressed proteins involved in CIA pathogenesis
were investigated for their potential as biomarkers.
We report here the findings of our search for useful
scoring methods and valuable biomarkers to monitor
different aspects of disease severity in CIA. First, we can
conclude that a combined analysis of scoring X-ray’s
using a modified Larsen score and quantification of ero-
sions on the calcaneus as visualized by micro-CT ima-
ging is predictive for both cartilage damage and bone
erosions in CIA. Out of the selected proteins in our
study, a combined analysis of serum MMP-3 and anti-
collagen IgG2a antibody concentrations turned out to
be indicative not only for the inflammatory aspect of
CIA but also for cartilage and bone destruction, empha-
sizing the inflammatory nature of the disease. Most
important, in an independent experiment, this set of
proposed parameters is capable of accurately represent-
ing variations in disease severity induced by different
therapies. Taken together, this critical analysis of read-
outs for monitoring disease activity and therapeutic
responses in the CIA model has led to the identification
of parameters that allow faster analysis of treatment
efficacy with minimal loss of information.
Materials and methods
Mice
Male, 9 to 10-week-old DBA/1 mice were purchased
from Janvier (Le Genest Saint Isle, France) and housed
following institutional guidelines. Experiments were con-
ducted according to the guidelines of the Ethics Com-
mittee of Laboratory Animals Welfare of Ghent
University.
Induction and analysis of CIA
Mice were immunized intradermally at the base of the
tail with 200 μg of chicken type II collagen (CII) (Mor-
well Diagnostics GmbH, Zurich, Switzerland) (in 0.1 M
acetic acid) emulsified in Incomplete Freund’s Adjuvant
+ mycobacterium Tuberculosis H37RA (150 μg/mouse)
(Difco, Lawrence, KS, USA). Twenty-one days later,
mice were re-challenged with an injection of CII in
Incomplete Freund’s Adjuvant. From Day 21, mice were
monitored for clinical symptoms of arthritis until the
day of sacrifice (Day 42). Clinical severity was graded as
follows: 0 = normal; 0.5 = erythema and edema in only
one digit; 1 = erythema and mild edema of the footpad,
or ankle or two to five digits; 2 = erythema and moder-
ate edema of two joints (footpad, ankle, two to five
digits); 3 = erythema and severe edema of the entire
paw; 4 = reduced swelling and deformation leading to
incapacitated limb.
The individual mouse arthritic score was obtained by
summing the scores recorded for each limb. Clinical
evaluations were performed by two investigators una-
ware of mouse identity and the mean of both scores was
calculated.
Semi-therapeutic treatment of CIA
From Day 20 after primary immunization, mice were
treated with one of four different therapies: 1) dexa-
methasone (Organon Laboratories Ltd, Hertfordshire,
UK) (1 mg/kg, daily, intraperitoneal injection); 2) etaner-
cept (Wyeth Pharmaceuticals, Louvain-la-Neuve, Bel-
gium) (15 mg/kg, every other day, intraperitoneal
injection); 3) zoledronic acid (Novartis, Basel, Switzer-
land) (100 μg/kg, one single injection on Day 20, subcu-
taneous injection); 4) abatacept (Bristol-Myers-Squibb,
NY, NY, USA) (5 mg/kg, every other day, intraperito-
neal). As a control, mice were similarly treated with
phosphate buffered saline (PBS).
Scoring of X-ray images
Prior to histology, anteroposterior X-ray radiographs
were taken (Faxitron M20, Edimex, France) of one hind
paw per mouse. The severity of bone erosion was
blindly ranked by three independent scorers using a
modified version of the Larsen scoring method: 0 = nor-
mal; 1 = slight abnormality with any one or two of the
exterior metatarsal bones showing slight bone erosion;
2 = definite early abnormality with any of the metatarsal
or tarsal bones showing bone erosion; 3 = medium
destructive abnormality with the metatarsal bones or
any one or two of the tarsal bones showing definite
bone erosions; 4 = severe destructive abnormality with
all the metatarsal bones showing definite bone erosion
and at least one of the tarsometatarsal joints being com-
pletely eroded, leaving some bony joint outlines partly
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preserved; 5 = mutilating abnormality with no bony
outlines that can be deciphered.
X-ray microcomputed tomography analysis (micro-CT)
3 D micro-tomodensitometry of calcaneus (Skyscan
11.70, Kontich, Belgium; X-ray voltage: 60 kV; current:
100 μA; 1,000 × 600 large camera resolution) was used
to quantify bone erosion within the paws. Image analysis
(CTAn software, Skyscan) allowed quantification of the
mean number of objects per slice.
Histological evaluation
To allow comparison between the different techniques,
histology was performed on the same paws that were
used for X-ray and micro-CT imaging. Knees and paws
were fixed in 4% formaldehyde, decalcified and
embedded in paraffin. Serial sections of the knee were
stained with hematoxylin and eosin (H&E) or with saf-
franin O-fast green and inflammation and joint damage
of the femorotibial joint were investigated by scoring
five parameters as follows: inflammation was scored on
a scale of 0 (no inflammation) to 3 (severe inflamed
joint) depending on the number of inflammatory cells in
the synovial cavity (exudate) and synovial tissue (infil-
trate). Exudate and inflammatory infiltrate were both
assigned individual scores. Loss of proteoglycans was
scored on a scale of 0 to 3, ranging from fully stained
cartilage to destained cartilage or complete loss of
articular cartilage. Cartilage destruction was scored on a
scale of 0 to 3, ranging from the appearance of dead
chondrocytes (empty lacunae) to complete loss of the
articular cartilage. Loss of bone was scored on a scale of
0 to 5 ranging from no damage to complete loss of the
bone structure [9]. We also stained serial sections of the
paw and examined the following parameters: pannus
severity, infiltrate, cartilage lesion and bone lesion. The
scoring system ranged from 1 to 4: 1 = normal, 2 =
mild, 3 = moderate, 4 = severe.
For both knee and paw histology, a composite score
was calculated by summing the individual parameters.
Scoring was executed blindly by two investigators and
mean values were calculated.
Serum analyses
Serum was collected at the end of the experiments.
Standard ELISA kits were used for determination of
serum levels of anti-CII specific IgG1 (Chondrex, Red-
mond, WA, USA) and IgG2a (MD Biosciences, Zurich,
Switzerland) antibodies, COMP (AnaMar Medical, Göte-
borg, Sweden), MMP-3 (R&D Systems, Abingdon, UK)
and C-terminal cross-linking telopeptide of type I col-
lagen (CTX I) (RatLaps EIA) and CTX II (Serum Pre-
Clinical Cartilaps ELISA) (both from Immunodiagnostic
Systems, Boldon Business Park, UK).
Levels of interleukin (IL)-6, IL-17, Keratinocyte
chemoattractant (KC) and TNF-a were determined by a
Luminex Beadlyte kit (4-plex) (Upstate, VA, USA).
Statistical analysis
For analysis of longitudinal clinical scores, mixed model
analysis with random intercept was used. Differences in
clinical (day of onset and Day 42 score) and histological
data between the treatment groups were assessed by
Kruskal Wallis tests followed by Mann-Whitney-U test
with correction using the Holm procedure. Fisher’s
Exact test was applied to analyse arthritis frequencies.
Stepwise linear regression analysis was performed with
the scoring methods, serum markers and treatment
group as covariates. All analyses were performed using
SPSS 15.0 statistical software (Chicago, IL, USA).
Results
Evaluation of CIA by clinical and histological examination
We initiated this study by examining CIA severity using
the current gold standard method: clinical scoring fol-
lowed by histological analysis. To create gradations in
disease severity, mice were treated semi-therapeutically
with one of four different therapies: dexamethasone, eta-
nercept, zoledronic acid or abatacept. Vehicle (PBS)
administration was used as a negative control. Pooled
data of two independent experiments are shown in
Figure 1A and Table 1. As expected, semi-therapeutic
treatment of mice with dexamethasone completely abol-
ished the induction of CIA. Also etanercept induced sig-
nificant improvement in arthritis symptoms. Treatment
with abatacept on the other hand resulted in a small,
albeit not significant, reduction in disease severity and
one-time administration of zoledronic acid showed no
protective effect.
In contrast to clinical scoring, which is mainly indica-
tive of the degree of inflammation, histological examina-
tion provides additional information pertaining to
cartilage and bone damage. In line with the absence of
clinical symptoms, histological scoring of the knee joint
revealed no signs of inflammation (inflammatory infil-
trate and exudate), proteoglycan depletion, destruction
of articular cartilage or bone erosion in dexamethasone
treated animals (Figure 1B). Although the composite
score of knee histology was borderline not significant
after statistical correction using the Holm procedure
(P = 0.019 > 0.017 (Holm)), the attenuated clinical dis-
ease activity observed in mice treated with etanercept
was in agreement with strong reductions in the five
parameters analysed when compared to vehicle treated
mice. Comparable to a rather small improvement of
clinical arthritic symptoms in the abatacept treated
mice, all histological parameters investigated showed a
moderate reduction in severity. Treatment with
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zoledronic acid did not induce improvement in any of
the histological factors. In the context of the four thera-
pies used, similar trends were observed between the his-
tological assessment of disease and the clinical score.
Beside the knee joint, also hind paw joints are com-
monly subjected to histological examination and in the
present study, we examined the correlation between
both techniques and the clinical score. Based on our
results, it can be concluded that although clinical scor-
ing addresses paw inflammation, histological examina-
tion of the knee joint correlates slightly better with the
clinical scoring as compared to paw histological scoring
(r = 0.725 and r = 0.533 for histology composite scores
of respectively knee and paw versus clinical scoring on
Figure 1 A) Clinical scoring of arthritis symptoms in CIA. From Day 20 after CIA induction, mice received semi-therapeutic treatment with
one of four therapies: dexamethasone (n = 23), etanercept (n = 23), zoledronic acid (n = 24) or abatacept (n = 23). Control mice were treated
with the vehicle PBS (n = 24). Signs of arthritis were monitored until Day 42. Significant reduced arthritis scores were observed for
dexamethasone and etanercept treatment as compared to PBS administration (mixed model analysis, random intercept, P < 0.001 for both
dexamethasone and etanercept). Means + SEM of pooled data from two independent experiments are depicted. B) Histological examination
of arthritis symptoms in the knee joint of CIA mice. At Day 42 post-immunization, knee joints were isolated and prepared for histological
examination. Femorotibial joints were scored for five different parameters. Kruskall-Wallis test: P ≤ 0,001 for all parameters as compared to PBS. *:
significant P-values (compared to PBS) according to Mann-Whitney U test and correction using the Holm procedure. Bars represent means +
SEM.
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Day 42). These findings highlight the fact that CIA is a
systemic disease and that both sites are useful for histo-
logical examination.
Scoring of plain X-ray and micro-CT images are valuable
methods to assess cartilage and bone damage in CIA
Despite the fact that histology provides additional infor-
mation on cartilage and bone damage, the procedure is
time-consuming and only allows cross-sectional analysis.
We therefore compared the use of two non-invasive
scoring techniques based on X-ray and micro-CT ima-
ging of paws, with both clinical and histological scoring.
For scoring of plain X-ray images, a modified Larsen
score was applied on hind paws of the mice. On recon-
structed three-dimensional micro-CT images, the focal
bone erosion at the calcaneus is clearly visible (Figure
2). This bone erosion was quantified by counting the
average number of objects per slice on the 2 D micro-CT
images of the calcaneus, using image analysis software.
For further analysis, stepwise linear regression model-
ling was performed on data from a first experiment. Lin-
ear regression analysis, using a clinical score on Day 42
as the dependent variable and composite scores for knee
and paw histology, Larsen score, micro-CT calcaneus
score and treatment group as independent variables,
indicates that from these four different scoring methods,
clinical scoring is most accurately represented by the
composite score of knee histology (adjusted R2 = 0.464).
Despite this strong correlation between the clinical
score and knee histology, we opted to investigate the
capacity of X-ray or micro-CT imaging, performed on
paws, to predict joint damage, in relation to histology of
the paw. Therefore, two linear regression analyses with
either the cartilage or bone parameter of the paw histol-
ogy as dependent variable were fitted (Table 2). Results
suggested that the Larsen score was most indicative for
cartilage destruction in the paw, but the predictive value
of the regression model was greatly enhanced by addi-
tion of the calcaneus erosion score and the clinical
score (R2 = 0.704). However, for the detection of bone
erosions, the calcaneus score showed the best correla-
tion with histology yet, combined analysis of calcaneus
and Larsen score was much more predictive for bone
erosions (R2 = 0.713). These results indicate that a com-
bined analysis of clinical score, X-ray Larsen score and
micro-CT calcaneus score provide useful information
regarding cartilage and bone destruction in CIA.
MMP-3 is related to inflammation as well as cartilage and
bone damage in CIA
For the identification of biomarkers to assess disease
severity in CIA, the concentrations of 10 serum proteins
were assessed at the time of sacrifice. The selected pro-
teins constitute inflammatory mediators and chemokines
involved in arthritis, including TNF-a, IL-17, IL-6,
MMP-3 and KC. Additionally, indicators of cartilage
degradation (COMP and CTXII) and bone damage
(CTXI) were determined as well as the presence of anti-
bodies to type II collagen (IgG1 and IgG2a). As serum
levels of IL-6 were mostly undetectable, this cytokine
was eliminated from further analysis.
Although analysis on the individual biomarker level
revealed significant correlations with clinical score, carti-
lage destruction and bone erosion for five out of nine
proteins (COMP, CTXII, CTXI, anti-collagen IgG2a and
MMP-3) (data not shown), only three of them contribu-
ted significantly in the performed linear regression mod-
els. No significant correlations were observed for the
investigated cytokines (IL-17 and TNF-a). In three mod-
els with clinical score, or cartilage or bone destruction
of the knee histology as dependent variables, we incor-
porated all nine proteins, including the cytokines, and
the treatment group (Table 3). Remarkably, measure-
ment of MMP-3 concentrations in serum was found to
Table 1 Overview of pooled clinical data from two individual experiments
Incidence of arthritis Day of onset of arthritis Day 42 score
Treatment
groups
N Frequency of
arthritis (%)
P-value (Fisher’s
exact test)
Median IQR P- value (MW)
(compared to PBS)
Median IQR P- value (MW)
(compared to PBS)
Vehicle (PBS) 24 87.5 29 26 to
33
3.25 3 to 6
Dexamethasone 23 4.3 0.000* ND ND ND 0 0 to 0 0.000*
Etanercept 23 69.6 0.168* 33 23 to
35
0.600 0.5 0 to
3.5
0.004*
Zoledronic acid 24 83.3 1.000* 31 28 to
32
0.212 4.5 0.625
to 6
0.840*
Abatacept 23 73.9 0.286* 28 25 to
32
0.400 3 0 to 7 0.378*
Depicted are the number of mice (N), frequency of arthritis at Day 42, median day of onset and median arthritis score at Day 42 with their interquartile range
(IQR) and P-values (*: significant P-values according to Mann-Whitney U test (MW) and correction using the Holm procedure). Fisher’s exact test for frequencies of
arthritis: P < 0.001; Kruskall Wallis test for day of onset: P = 0.349; Kruskall Wallis test for Day 42 score: P < 0.001. ND, not determined. PBS, phosphate buffered
saline.
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be most indicative for clinical score. Analysis of histolo-
gical parameters revealed that MMP-3 is not only a
good indicator for the inflammatory aspect of CIA but
also for cartilage and bone damage. Addition of anti-col-
lagen IgG2a to the models improved the association
with clinical score and bone destruction. Combined
detection of both MMP-3 and CTXII on the other hand
was more indicative for cartilage destruction.
Validation of the proposed regression models
To validate the obtained results, the data set from a sec-
ond independent experiment was fit in the regression
equations derived from the initial analyses, resulting in
predicted values. Because linear regression analysis,
combining scoring methods and serum markers, did not
yield important contributions for serum markers in pre-
dicting cartilage and bone degradation (Table 4), these
aspects of the disease were only validated using X-ray
and micro-CT analysis. Clinical score on the other
hand, was predicted using MMP-3 and anti-collagen
IgG2a antibody concentrations. In the validation ana-
lyses, we studied the capacity of the predicted values to
distinguish between the different therapies. As CIA
experiments are always performed on a group of ani-
mals and not on the individual level, we opted to per-
form the validation analysis on the level of the
treatment groups. Figure 3 clearly demonstrates that the
same trends between the different treatment groups can
be detected in the graphical representations of both the
observed and predicted values for the clinical score, car-
tilage degradation and bone destruction. This was con-
firmed by very strong correlations between the observed
and predicted mean values for each treatment group
(Spearman’s rho = 0.94, R = 0.99 and R = 0.99 for pre-
dicted versus observed means of respectively clinical
score, cartilage destruction and bone erosions). These
validation analyses provides compelling evidence
that the proposed read-out parameters, MMP-3,
Figure 2 Visualisation of joint damage by X-ray and micro-CT imaging. A) X-ray pictures of representative paws from naive and treated or
untreated CIA mice. B) Three-dimensional reconstructions of micro-CT images of representative calcaneus bones from naive and treated or
untreated CIA mice.
Table 2 Best-fit models for clinical score, and cartilage and bone destruction predicted by different scoring methods
Dependent variable Best-fit model Adjusted R2 Significance
Clinical score Composite score of knee histology 0.464 < 0.001
Cartilage destruction Larsen score 0.525 < 0.001
Larsen score + micro-CT calcaneus score 0.667 < 0.001
Larsen score + micro-CT calcaneus score + clinical score 0.704 < 0.001
Bone destruction Micro-CT calcaneus score 0.605 < 0.001
Micro-CT calcaneus score + Larsen score 0.713 < 0.001
Best-fit models for clinical score, and cartilage and bone destruction in the hind paw as proposed by linear regression analysis with scoring methods and
treatment group as independent variables. R2 indicates the squared correlation between the observed values of the dependent variable and the predicted values
based on the regression model. Adjusted R2 is a modification of R2 that adjusts for the number of covariates in the regression model.
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anti-collagen IgG2a, and Larsen and micro-CT calca-
neus score, are most applicable to detect changes in
different aspects of arthritis severity upon treatment.
Discussion
As in many other human or experimental diseases, the
field of surrogate analysis markers is also in RA and its
experimental models of increasing importance. There-
fore, it is surprising that a comprehensive analysis,
aimed at assessing various read-out parameters for mon-
itoring disease activity is still lacking for CIA, the most
commonly used animal model of RA. In this report, we
use linear regression analysis to propose a restricted set
of key indicators that allows the assessment of CIA in a
more objective and less labour-intensive way.
When evaluating the value of serum markers, MMP-3
was found to be highly indicative of all the features of
CIA, including inflammation, cartilage destruction and
bone erosion. This is in line with previous reports that
demonstrated elevated MMP-3 expression levels in
synovial fluids and sera of patients with rheumatoid
arthritis as well as expression in joints of CIA rats
[10-12]. Although several studies have proposed MMP-3
as a useful indicator for inflammation in RA, the corre-
lation of MMP-3 with joint destruction or its predictive
value is still a matter of debate [10,13-18]. Our results,
however, showed a strong correlation of this marker
with joint damage. A second marker that also proved to
be related to inflammation and bone destruction is the
anti-CII IgG2a antibody. Antibodies to CII are detected
in both human as well as experimental arthritis early in
disease development and the IgG2 subclass is capable of
initiating inflammatory processes by activating the com-
plement cascade [8,19-21].
Rather unexpected was the finding that, in combina-
tion with MMP-3 and anti-collagen IgG2a, detection of
cartilage or bone degradation products such as COMP
and CTXI in serum could not improve the predictive
value of the regression models for cartilage or bone
destruction as assessed by knee histology. However, CIA
is an experimentally induced arthritis that is strongly
mediated by inflammation. This could clarify why
inflammatory mediators rather than specific indicators
of cartilage and bone degradation proved to be better
biomarkers in this animal model. In addition, since the
serum levels for the different markers were assessed at
the end of the study, different kinetics of the COMP or
CTXI markers might represent another explanation for
their lower predictive value observed in this study. This
possibility of different kinetics could also provide an
explanation for the fact that the inflammatory cytokines
TNF-a and IL-17 did not correlate with clinical score
and joint damage.
We also evaluated the potential of different imaging
techniques to assess disease activity in CIA, which
yielded a second set of important findings. First, scoring
of X-ray pictures using a modified Larsen score was
most indicative for destruction of cartilage. It should be
mentioned though that cartilage itself cannot be visua-
lised by X-rays. Therefore, cartilage destruction is quan-
tified indirectly by incorporating joint space narrowing
as a parameter in the scoring system. Second, for the
assessment of bone erosions, we introduced a rather
new method that is based on micro-CT imaging and
allows objective and high throughput analyses. So far,
bone loss on micro-CT was mainly studied using para-
meters describing bone volume and composition [22,23].
Table 3 Best-fit models for clinical score, and cartilage
and bone destruction predicted by different serum
markers
Dependent
variable
Best-fit model Adjusted
R2
Significance
Clinical score MMP-3 0.414 < 0.001
MMP-3 + anti-collagen
IgG2a
0.499 < 0.001
Cartilage
destruction
MMP-3 0.451 < 0.001
MMP-3 + CTXII 0.485 < 0.001
Bone destruction MMP-3 0.372 < 0.001
MMP-3 + anti-collagen
IgG2a
0.411 < 0.001
Best-fit models for clinical score, and cartilage and bone destruction in the
knee joint as proposed by linear regression analysis with nine serum markers
and treatment group as independent variables. MMP-3, matrix
metalloproteinase-3.
Table 4 Best-fit models for cartilage and bone destruction predicted by both scoring methods and serum markers
Dependent variable Best-fit model Adjusted R2 Significance
Cartilage destruction Larsen score 0.530 < 0.001
Larsen score + micro-CT calcaneus score 0.664 < 0.001
Larsen score + micro-CT calcaneus score + clinical score 0.700 < 0.001
Bone destruction Micro-CT calcaneus score 0.602 < 0.001
Micro-CT calcaneus score + Larsen score 0.711 < 0.001
Micro-CT calcaneus score + Larsen score + COMP 0.731 < 0.001
Best-fit models for cartilage and bone destruction in the paw as proposed by linear regression analysis with all scoring methods and serum markers and
treatment group as independent variables. COMP, cartilage oligomeric matrix protein.
Seeuws et al. Arthritis Research & Therapy 2010, 12:R160
http://arthritis-research.com/content/12/4/R160
Page 7 of 10
Figure 3 Validation of the proposed regression models. Graphical reproduction of the observed and predicted values for clinical score,
cartilage destruction and bone erosions based on a second independent data set. Predicted values were calculated using the linear regression
equations obtained from the first experiment. Bars represent means + SEM and r = Spearman’s rho representing the correlations between the
observed and predicted mean values for each treatment group.
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A major hallmark of RA and CIA, however, is the
appearance of focal bone erosions [24] and to quantify
these erosions we calculated the number of objects on
slices through the calcaneus as a measure for bone frag-
mentation. Our analysis showed that this method corre-
lated well with the bone erosion score of histology.
Importantly, in both cases, combined analysis of X-ray
Larsen and micro-CT calcaneus score greatly enhanced
the predictive values of the regression models for carti-
lage and bone destruction. Both X-ray and micro-CT
imaging allow longitudinal follow-up of disease activity
in animals. However, our analyses only take into
account the read out-parameters on Day 42 and as
such, they do not allow us to draw conclusions about
the utility and sensitivity of these methods at earlier
time points. A follow-up study comparing the techni-
ques at different time-points of disease progression
could answer this question. Additionally, it would also
yield useful information about the predictive value of
the techniques and it could indicate if a correct analysis
for the different aspects of the disease severity in CIA
could be obtained at an earlier time-point to shorten
the experiment time.
Remarkably, when linear regression analyses, contain-
ing both serum markers and scoring methods, were per-
formed, results demonstrated that serum markers did not
increase the predictive value of the models for cartilage
and bone damage. This implies that serum markers are
inferior to imaging methods for the evaluation of disease
activity and therapeutic efficacy. One can however not
conclude that a role for the investigated serum markers
in CIA is minimal. As already mentioned, serum levels of
proteins may display certain kinetic patterns in patholo-
gies and as such, timing of the evaluation could be
important. Furthermore, serum concentrations of pro-
teins do not necessarily reflect the local situation in the
joint. Investigation of biomarker expression in the joint
would yield useful information but these methods are
often more invasive and as such less applicable.
Validation of the obtained results by utilizing an inde-
pendent data set, demonstrated that values, predicted by
the proposed read-out parameters, were also capable to
differentiate between various therapies with a different
mode of action. The same trends between the different
treatment modalities could be observed in the graphical
representations of both the predicted values by Larsen
and calcaneus score and the values observed by histolo-
gical examination. Since the last method is very time-
consuming and only allows cross-sectional analysis,
combined analysis of X-ray and micro-CT images might
provide a worthy alternative. One should, however, also
take in mind that the analyses performed in our study
focus on the utility of different read-out parameters to
assess disease severity in CIA. As different animal
models exist to investigate rheumatoid arthritis, for
example, adjuvant-induced arthritis, zymosan induced
arthritis and so on, a comparable study should be per-
formed for all the other models. Similarly, it would be
interesting to investigate the value of imaging techni-
ques and serum markers in other joint disorders, such
as osteoarthritis. In other words it remains to be deter-
mined whether imaging techniques and serum markers
also apply in other models of experimental arthritis.
Conclusions
We can conclude that MMP-3 is a strong indicator for
the inflammatory features of CIA. The fact that this
marker is also related to cartilage and bone destruction
emphasizes the inflammatory nature of the disease.
Furthermore, combined analysis of X-ray Larsen and
micro-CT calcaneus erosion score proved to be predic-
tive for both cartilage and bone destruction. Overall, our
analyses revealed that clinical scoring, combined with
serum MMP-3 and anti-collagen IgG2a measurement
and scoring of X-ray and micro-CT images yield a com-
prehensive insight into the different aspects of disease
activity in CIA.
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